👍_老虎社区_美港股上老虎

达人666
2021-09-29

👍

Hold Off on eFFECTOR Therapeutics if You Can’t Stomach the Risk

EFTR stock will most likely encounter some serious chop. As you may be aware, some business combina

Hold Off on eFFECTOR Therapeutics if You Can’t Stomach the Risk

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":862218110,"tweetId":"862218110","gmtCreate":1632880890847,"gmtModify":1632880890847,"author":{"id":3576120003586121,"idStr":"3576120003586121","authorId":3576120003586121,"authorIdStr":"3576120003586121","name":"达人666","avatar":"https://static.tigerbbs.com/85ef10d969f5c4cc1c22dcf24800011d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>👍</body></html>","htmlText":"<html><head></head><body>👍</body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/862218110","repostId":1138585849,"repostType":4,"repost":{"id":"1138585849","kind":"news","pubTimestamp":1632878922,"share":"https://www.laohu8.com/m/news/1138585849?lang=&edition=full","pubTime":"2021-09-29 09:28","market":"us","language":"en","title":"Hold Off on eFFECTOR Therapeutics if You Can’t Stomach the Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=1138585849","media":"InvestorPlace","summary":"EFTR stock will most likely encounter some serious chop.\n\nAs you may be aware, some business combina","content":"<blockquote>\n EFTR stock will most likely encounter some serious chop.\n</blockquote>\nAs you may be aware, some business combinations with special purpose acquisition companies (SPACs) have not gone well. But oneexception— at least so far — is&nbsp;<a href=\"https://laohu8.com/S/EFTR\">Effector Therapeutics, Inc.</a> and EFTR stock.\n<img src=\"https://static.tigerbbs.com/729193d6f79705fac6076fe3aca64720\" tg-width=\"300\" tg-height=\"169\" referrerpolicy=\"no-referrer\">Source: <a href=\"https://laohu8.com/S/SSTK\">Shutterstock</a>\nThis clinical-stage biotechnology firm focuses onselective translation regulation inhibitors(STRIs) in cancer. EFTR stock is currently up some 43% year-to-date (YTD).\nHow is EFTR different from the pack? And does it mean you should invest? Here’s what you should know about the company and its stock moving forward.\nEFTR Stock: Potentially on the Cutting Edge\nThere are three key reasons why shares of this name have moved against the SPAC grain so far. But first, let’s address the obvious: EFTR stock is incredibly popular on social media. Whether it’s a meme trade or not, I’ll leave to readers. Still, it certainly has some similar qualities.\nSecondly, EFTR stock has lit up the charts because of its relevance. <a href=\"https://laohu8.com/S/LBIX\">Leading</a> up to mitigation protocols addressing Covid-19, the pharmaceutical industry was hotlypursuing oncological drugs. Sector analysts saw the enthusiasm as unprecedented. So, given that eFFECTOR could hold the key to groundbreaking cancer therapeutics, it’s only natural that interest has reignited. (Plus, with the easing of the pandemic, more patients are willing to visit treatment facilities, indirectly helping the case for the stock).\nThirdly, though, the pandemic itself has been a boon for novel therapeutics. Prior to companies like<a href=\"https://laohu8.com/S/PFE\">Pfizer</a>(NYSE:PFE) andModerna(NASDAQ:MRNA) rolling out their mRNA vaccines, the U.S. Food and Drug Administration (FDA) hadnever approvednucleic-acid-based vaccines. Because of research insights into various new biotechnologies, eFFECTOR has a much more credible investment profile.\nDespite Industry Gains, eFFECTOR Is Still Risky\nHowever, although the experiences of the pandemic have improved EFTR stock’s probability of success, where that improvement puts it against the bigger picture is still unclear. For instance, animprovementof probability from 1% to 2% is a difference of 100%, yet a 2% probability is still not at all encouraging.\nTo be absolutely clear, I’m not saying that EFTR has a 2% chance of success. Frankly, I’m not even sure you can accurately measure the success rates of biotech names because they’re so volatile. With both investors and scientists pouring over the data left and right, all it takes is <a href=\"https://laohu8.com/S/AONE.U\">one</a> small aspect to go wrong and the name in question can crumble.\nAnd that’s really the point of EFTR stock. Yes, it has enjoyed great returns over a short period of time. But never forget the cruel nature of biotech investing — you can lose those gains (and then some)just as quickly.\nOf course, bulls will be quick to point out that the company has anongoing collaborationwith Pfizer. Fresh from its Covid-19 vaccine success, Pfizer has nothing but momentum on its side. At the same time, though, big pharmaceutical firms don’t necessarily have agreat track recordof delivering clinical results.\nAt least, that’s according to aStatop-ed from December 2019, right before the pandemic. The piece found that “large pharmaceutical companies did not actually invent most of the drugs they sell.” Many of the drugs that reached the commercial phase came from third parties. In other words, the Pfizer name could end up being a red herring here.\nUltimately, though, many (if not most) of the new therapeutics attempting to go through various clinical phasessimply never make it to market. Therefore, you’re taking a huge risk with EFTR stock regardless.\nEFTR Stock: Beware of the Crowd\nThe appeal for eFFECTOR investors is that — should the company reach commercial success or be bought out by another firm — the price you pay today for EFTR stock could turn out to be a tremendous discount.\nAnd after all, you don’t gain anything if you don’t risk anything. I invest in cryptos, so I totally understand the nature of the beast.\nStill, if you’re thinking about EFTR stock, you’ve got to be careful. When looking at many of the meme (or meme-like) trades, the technical patterns can be stunningly nonsensical. Is this the next generation ofgroup dynamics? Whatever it is, you’ve got to know what you’re doing and the risks involved.\nIf you’re okay with that, then EFTR might work out for you. But I hope you’ll excuse me for not joining in on the fun.","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hold Off on eFFECTOR Therapeutics if You Can’t Stomach the Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHold Off on eFFECTOR Therapeutics if You Can’t Stomach the Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 09:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/09/hold-off-eftr-stock-effector-therapeutics-if-you-can-stomach-risk/>InvestorPlace</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\nEFTR stock will most likely encounter some serious chop.\n\nAs you may be aware, some business combinations with special purpose acquisition companies (SPACs) have not gone well. But oneexception— at ...\n\n<a href=\"https://investorplace.com/2021/09/hold-off-eftr-stock-effector-therapeutics-if-you-can-stomach-risk/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"EFTR":"eFFECTOR Therapeutics, Inc."},"source_url":"https://investorplace.com/2021/09/hold-off-eftr-stock-effector-therapeutics-if-you-can-stomach-risk/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138585849","content_text":"EFTR stock will most likely encounter some serious chop.\n\nAs you may be aware, some business combinations with special purpose acquisition companies (SPACs) have not gone well. But oneexception— at least so far — is Effector Therapeutics, Inc. and EFTR stock.\nSource: Shutterstock\nThis clinical-stage biotechnology firm focuses onselective translation regulation inhibitors(STRIs) in cancer. EFTR stock is currently up some 43% year-to-date (YTD).\nHow is EFTR different from the pack? And does it mean you should invest? Here’s what you should know about the company and its stock moving forward.\nEFTR Stock: Potentially on the Cutting Edge\nThere are three key reasons why shares of this name have moved against the SPAC grain so far. But first, let’s address the obvious: EFTR stock is incredibly popular on social media. Whether it’s a meme trade or not, I’ll leave to readers. Still, it certainly has some similar qualities.\nSecondly, EFTR stock has lit up the charts because of its relevance. Leading up to mitigation protocols addressing Covid-19, the pharmaceutical industry was hotlypursuing oncological drugs. Sector analysts saw the enthusiasm as unprecedented. So, given that eFFECTOR could hold the key to groundbreaking cancer therapeutics, it’s only natural that interest has reignited. (Plus, with the easing of the pandemic, more patients are willing to visit treatment facilities, indirectly helping the case for the stock).\nThirdly, though, the pandemic itself has been a boon for novel therapeutics. Prior to companies likePfizer(NYSE:PFE) andModerna(NASDAQ:MRNA) rolling out their mRNA vaccines, the U.S. Food and Drug Administration (FDA) hadnever approvednucleic-acid-based vaccines. Because of research insights into various new biotechnologies, eFFECTOR has a much more credible investment profile.\nDespite Industry Gains, eFFECTOR Is Still Risky\nHowever, although the experiences of the pandemic have improved EFTR stock’s probability of success, where that improvement puts it against the bigger picture is still unclear. For instance, animprovementof probability from 1% to 2% is a difference of 100%, yet a 2% probability is still not at all encouraging.\nTo be absolutely clear, I’m not saying that EFTR has a 2% chance of success. Frankly, I’m not even sure you can accurately measure the success rates of biotech names because they’re so volatile. With both investors and scientists pouring over the data left and right, all it takes is one small aspect to go wrong and the name in question can crumble.\nAnd that’s really the point of EFTR stock. Yes, it has enjoyed great returns over a short period of time. But never forget the cruel nature of biotech investing — you can lose those gains (and then some)just as quickly.\nOf course, bulls will be quick to point out that the company has anongoing collaborationwith Pfizer. Fresh from its Covid-19 vaccine success, Pfizer has nothing but momentum on its side. At the same time, though, big pharmaceutical firms don’t necessarily have agreat track recordof delivering clinical results.\nAt least, that’s according to aStatop-ed from December 2019, right before the pandemic. The piece found that “large pharmaceutical companies did not actually invent most of the drugs they sell.” Many of the drugs that reached the commercial phase came from third parties. In other words, the Pfizer name could end up being a red herring here.\nUltimately, though, many (if not most) of the new therapeutics attempting to go through various clinical phasessimply never make it to market. Therefore, you’re taking a huge risk with EFTR stock regardless.\nEFTR Stock: Beware of the Crowd\nThe appeal for eFFECTOR investors is that — should the company reach commercial success or be bought out by another firm — the price you pay today for EFTR stock could turn out to be a tremendous discount.\nAnd after all, you don’t gain anything if you don’t risk anything. I invest in cryptos, so I totally understand the nature of the beast.\nStill, if you’re thinking about EFTR stock, you’ve got to be careful. When looking at many of the meme (or meme-like) trades, the technical patterns can be stunningly nonsensical. Is this the next generation ofgroup dynamics? Whatever it is, you’ve got to know what you’re doing and the risks involved.\nIf you’re okay with that, then EFTR might work out for you. But I hope you’ll excuse me for not joining in on the fun.","news_type":1,"symbols_score_info":{"EFTR":0.9}},"isVote":1,"tweetType":1,"viewCount":1589,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}